Effect of Combined Folic Acid, Vitamin B-6, and Vitamin B-12 on Colorectal Adenoma

Harvard University, Cambridge, Massachusetts, United States
Journal of the National Cancer Institute (Impact Factor: 12.58). 10/2012; 104(20):1562-75. DOI: 10.1093/jnci/djs370
Source: PubMed


Background Folic acid, vitamin B6, and vitamin B12 act in concert in the one-carbon metabolism and may protect against colorectal neoplasia. We examined the effect of combined B-vitamin treatment on the occurrence of colorectal adenoma.Methods
The Women's Antioxidant and Folic Acid Cardiovascular Study was a randomized, double-blind, placebo-controlled trial of 5442 female health professionals at high risk for cardiovascular disease from April 1998 through July 2005. Participants were randomly assigned to receive a combination pill of folic acid (2.5mg), vitamin B6 (50mg), and vitamin B12 (1mg) or placebo. This study included 1470 participants who were followed up for as long as 9.2 years and underwent an endoscopy at any point during follow-up. We estimated relative risks using a generalized linear model with a natural logarithm link function and Poisson distributed errors. All statistical tests were two-sided. Results The risk of colorectal adenoma was similar among participants receiving treatment (24.3%, 180 of 741 participants) vs placebo (24.0%, 175 of 729 participants) (multivariable adjusted relative risk = 1.00, 95% confidence interval = 0.83 to 1.20). Treatment was not associated with the risk of adenoma when data were analyzed by subsite, size, stage, and the number of adenomas. There was no statistically significant effect modification by alcohol intake, history of cancer or adenoma, or baseline plasma levels or intakes of folate, vitamin B6, or vitamin B 12. Conclusion Our results indicate no statistically significant effect of combined folic acid, vitamin B6, and vitamin B12 treatment on colorectal adenoma among women at high risk for cardiovascular disease.

13 Reads
  • Source
    • "Biomarkers or dietary histories indicative of nutritional deficiencies associated with defects in one-carbon metabolism (for example, folate deficiency) have frequently been associated with an increased risk of cancer in epidemiological studies. Disappointingly, however, intervention trials have failed to demonstrate a reduction of cancer risk in individuals randomized to receive folic acid supplements compared to controls (Andreeva et al., 2012; Cole et al., 2007; Song et al., 2012; Zhang et al., 2008). This might suggest that folate deficiency correlates with, but does not cause, cancer or that folate is important during an early time window, perhaps occurring at an early age and prior to or during tumor initiation, but not thereafter . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chemical modifications of histones and DNA, such as histone methylation, histone acetylation, and DNA methylation, play critical roles in epigenetic gene regulation. Many of the enzymes that add or remove such chemical modifications are known, or might be suspected, to be sensitive to changes in intracellular metabolism. This knowledge provides a conceptual foundation for understanding how mutations in the metabolic enzymes SDH, FH, and IDH can result in cancer and, more broadly, for how alterations in metabolism and nutrition might contribute to disease. Here, we review literature pertinent to hypothetical connections between metabolic and epigenetic states in eukaryotic cells.
    Cell 03/2013; 153(1):56-69. DOI:10.1016/j.cell.2013.03.004 · 32.24 Impact Factor

  • Journal of the National Cancer Institute 10/2012; 104(20):1525-7. DOI:10.1093/jnci/djs412 · 12.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is difficult to diagnose in the child with sickle cell disease because symptoms and pulmonary function abnormalities are similar to the spectrum of pulmonary manifestations in sickle cell disease. There are no published reports of controlled trials of asthma medications in children with sickle cell disease. Thus, treatment decisions should be guided by the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma ( However, issues specific to children with sickle cell disease should be considered. Initial strategies should focus on control of environmental triggers, as effectiveness on asthma outcomes is proven and the cost for implementation can be low. Use of short- and long-acting beta(2)-agonists may prolong QTc, particularly in this population of children who already have a higher prevalence of prolonged QTc than the general population. Long-acting beta(2)-agonist use has been associated with life-threatening asthma exacerbations with potentially higher risks in African Americans. Montelukast has been reported to increase suicidal thinking and behavior, and persons with asthma and sickle cell disease are already at risk for these events. Oral corticosteroids in the treatment of acute chest syndrome may increase risk of readmission even in children with asthma. The lack of prospective controlled trials of asthma drug treatment in children with asthma and sickle cell disease compels us to move this issue forward.
    Pediatric Allergy, Immunology, and Pulmonology 03/2013; 26(1):43-47. DOI:10.1089/ped.2013.0124 · 0.66 Impact Factor
Show more